CN Patent

CN109957567B — 一种抑制PCSK9基因表达的siRNA分子及其应用

Assigned to Agna Biopharmaceutical Co ltd · Expires 2022-09-23 · 4y expired

What this patent protects

本发明涉及一种抑制PCSK9基因表达的siRNA分子及其药物组合物，以及使用所述siRNA分子或其药物组合物降低PCSK9基因表达水平的方法。该siRNA分子可用于治疗和/或预防PCSK9基因介导的疾病，包括心血管疾病和肿瘤性疾病。

USPTO Abstract

本发明涉及一种抑制PCSK9基因表达的siRNA分子及其药物组合物，以及使用所述siRNA分子或其药物组合物降低PCSK9基因表达水平的方法。该siRNA分子可用于治疗和/或预防PCSK9基因介导的疾病，包括心血管疾病和肿瘤性疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN109957567B
Jurisdiction
CN
Classification
—
Expires
2022-09-23
Drug substance claim
No
Drug product claim
No
Assignee
Agna Biopharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.